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A B S T R A C T   
Mutations in the MMADHC gene cause cobalamin D disorder (cblD), an autosomal recessive inborn disease with 
defects in intracellular cobalamin (cbl, vitamin B12) metabolism. CblD patients present methylmalonic aciduria 
(MMA), homocystinuria (HC), or combined MMA/HC, and usually suffer developmental delay and cognitive 
deficits. The most frequent MMADHC genetic alterations associated with disease generate MMADHC truncated 
proteins, in many cases due to mutations that create premature termination codons (PTC). In this study, we have 
performed a comprehensive and global characterization of MMADHC protein variants generated by all annotated 
MMADHC PTC mutations in cblD patients, and analyzed the potential of inducible translational PTC readthrough 
to reconstitute MMADHC biosynthesis. MMADHC protein truncation caused by disease-associated PTC differ-
entially affected the alternative usage of translation initiation sites, protein abundance, and subcellular locali-
zation of MMADHC. Aminoglycoside compounds induced translational PTC readthrough of MMADHC truncated 
variants, allowing the biosynthesis of full-length MMADHC in a PTC-specific manner. Our results suggest that 
translational PTC readthrough-based interventions could complement current therapies for cblD patients car-
rying specific MMADHC PTC mutations.   
1. Introduction 
Cobalamin (cbl) or vitamin B12 is one of the most essential enzy-
matic cofactors in cells, and it is required for normal cellular meta-
bolism. Only a few bacteria and archaea can produce cbl, and mammals 
lack the enzyme required for de novo cbl synthesis, making necessary its 
obtaining from animal products or supplements. Cbl is crucial for human 
development and survival, and its deficiency can cause a variety of 
health problems like megaloblastic anemias, respiratory or gastrointes-
tinal alterations, and neurologic dysfunctions with signs of demyelin-
ation, developmental delay, movement disorders and hypotonia, among 
others [1–4]. Inside the cell, cbl is converted into two cofactors, ade-
nosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). AdoCbl en-
ables the conversion in the mitochondria of L-methylmalonyl-coenzyme 
A into succinyl-coenzyme A by the methylmalonyl-coenzyme A mutase 
(MMUT; EC 5.4.99.2). Succinyl-coenzyme A is an essential metabolite 
for odd-chain fatty acid and some branched-chain amino acids catabo-
lism, before entering into the Krebs cycle. MeCbl acts as a cofactor for 
the methionine synthase (MS; 5-methyltetrahydrofolate:L-homocysteine 
S-methyltransferase; EC 2.1.1.13), which catalyzes in the cytosol the 
synthesis of methionine from homocysteine. MS is reactivated by the 
methionine synthase reductase ([methionine synthase]-methylcob(III) 
alamin,S-adenosyl-L-homocysteine:NADP+ oxidoreductase; EC 
1.16.1.8). Disruptions in these pathways cause several cbl-related 
metabolic multisystem disorders (cblA to cblG, cblJ, mut), which man-
ifest with elevated levels of methylmalonic acid and/or homocysteine 
[5]. Among these disorders the cblD-type disorder is a unique very rare 
disease associated with three distinct biochemical phenotypes: methyl-
malonic aciduria (MMA), homocystinuria (HC) or combined MMA/HC 
[6]. 
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MMADHC (methylmalonic aciduria and homocystinuria type D 
protein; cblD) protein is essential for the correct trafficking of cbl inside 
the cell, and inborn mutations at the MMADHC gene cause the distinct 
phenotypic manifestations of cblD disorder with an autosomal recessive 
pattern of inheritance [7,8]. Evidence indicates that MMADHC consti-
tutes the node of the cytosolic and mitochondrial cbl metabolic path-
ways [6,9], acting as an adaptor protein for MMACHC (cblC) in 
multiprotein complexes with MS and MS reductase [10–14]. MMADHC 
is a 296-amino acids (32.9 kDa) protein with an N-terminal disordered 
region (amino acids 1–107) containing a potential mitochondrial leader 
sequence (MLS; amino acids 1–12), and a C-terminal Nitro Reductase- 
like domain (NTR; amino acids 108–296) [7,12,15]. MMADHC pro-
vides a sulfur ligand to cbl bound to MMACHC [16], and the MMADHC 
NTR domain enhances the oxidation of cbl [15]. Genetic alterations in 
the MMADHC gene cause cblD-MMA, cblD-HC or cblD-MMA/HC, 
depending on the nature and localization of the mutation. Mutational/ 
functional analysis has delineated that the MMADHC N-terminal disor-
dered region is essential for AdoCbl synthesis, whereas the C-terminal 
NTR domain is essential for MeCbl synthesis. In this regard, cblD-MMA/ 
HC phenotype has been associated with MMADHC C-terminal trunca-
tions caused by premature termination codons (PTC), frameshift, or 
splicing-defect mutational events, whereas cblD-MMA phenotype has 
been associated with N-terminal truncations and missense mutations at 
the C-terminal NTR domain [7,17,18] (Fig. 1). 
Several genetic alterations identified in MMADHC gene are nonsense 
single-nucleotide substitutions resulting in PTC. This opens the possi-
bility of using induced translational PTC readthrough as a therapeutic 
approach to reconstitute the expression and function of full-length 
MMADHC proteins in specific cblD patients. Translational PTC read-
through can be induced by aminoglycoside and non-aminoglycoside 
compounds, which interfere with biosynthetic protein translation and 
increase the error in the decoding process at sites of premature termi-
nation of protein biosynthesis. As a consequence, amino acids encoded 
by near-cognate codons are incorporated at PTC positions, and a full- 
length protein is synthesized with variable efficiency, depending on 
the specific PTC and the PTC readthrough inducer [19–22]. 
The purpose of this study was to characterize the biochemical fea-
tures and subcellular localization of MMADHC variants derived from 
PTC mutations, and to analyze their translational readthrough in 
response to PTC inducers. Our results illustrate how specific disease- 
associated PTC affect MMADHC protein translation initiation, and 
show that induced PTC readthrough is effective to reconstitute full- 
length expression of specific MMADHC PTC variants. 
2. Materials and methods 
2.1. Plasmids and mutagenesis 
pRK5 HA-MMADHC has been previously described [23]. pRK5 
MMADHC-GFP was generated by direct subcloning of MMADHC-GFP 
cDNA, from pCMV3 MMADHC-GFP Spark (Sino Biologicals), into the 
pRK5 plasmid [24]. Human MMADHC nucleotide and protein entries 
are NM_015702 and NP_056517, respectively). Nucleotide substitutions 
were performed by PCR oligonucleotide-directed site directed muta-
genesis, as described [25]. All constructs and mutations were confirmed 
by digestion with specific restriction enzymes and DNA sequencing. 
2.2. Cell lines, cell cultures, and transfections 
Simian kidney COS-7 cells (ATCC) were grown at 37 ◦C and 5% CO2 
in DMEM (Dulbeccos’s Modified Eagle’s Medium, Lonza) with 5% heat- 
inactivated fetal bovine serum (FBS), 1 mM L-glutamine, 100 U/ml 
penicillin and 0.1 mg/ml streptomycin. Semi-confluent cells were 
incubated 16–24 h with GeneJet™ transfection reagent (SignaGen 
Laboratories) and the appropriate cDNA plasmids, according to the 
manufacturer specifications. Medium was changed 24 h after trans-
fection and cells were processed 48 h after. 
2.3. Readthrough induction 
The PTC readthrough inducers used were: G418 (Geneticin; Merck 
Millipore, #345810; 200 μg/ml, or the indicated dose in Fig. 4), 
gentamicin (Merck Millipore, #345815; 800 μg/ml), and amikacin 
(Merck Sigma Aldrich, #A03680; 2 mg/ml). The inducers were added 
24 h after changing transfection media, and cells were incubated for 
additional 24 h. For semi-quantitative determination of PTC read-
through efficiency, the full-length MMADHC-GFP protein bands were 
quantified using an Image studio™ software with Odyssey® CLx Imag-
ing System (LI-COR Biosciences). PTC readthrough efficiency was 
determined as the percentage of each full-length MMADHC-GFP PTC 
variant translated under PTC readthrough-inducing conditions 
compared to the translation of MMADHC-GFP wild type (100%). All 
quantifications are shown as the mean ± s.d. from at least two inde-
pendent experiments. 
2.4. Fluorescence microscopy, antibodies, and immunoblot 
For protein localization experiments by fluorescence microscopy, 
COS-7 cells expressing MMADHC-GFP were directly visualized using a 
Leica DMI 60000B fluorescent microscope. Cell nuclei were stained with 
Hoechst 33342 (ThermoFisher Scientific). For immunoblot, COS-7 cells 
were processed as described [26]. Briefly, cells were washed with PBS 
and lysed in ice-cold M-PER lysis buffer (ThermoFisher Scientific) sup-
plemented with PhosSTOP phosphatase inhibitor and complete protease 
inhibitor cocktails (Roche). The lysate was clarified by centrifugation at 
15,200g for 10 min at 4 ◦C. Supernatant (whole-cell extract) was 
collected and 50–100 μg of protein was mixed with NuPAGE LDS sample 
buffer (4×) (ThermoFisher Scientific) and boiled. Samples were resolved 
by 10%- or 12%-SDS-PAGE under reducing conditions, and transferred 
to PVDF membranes (Immobilon-FL, Millipore). Antibodies used were: 
rabbit polyclonal anti-GFP (G1544, Sigma Aldrich), mouse monoclonal 
anti-HA (12CA5, ThermoFisher Scientific), and mouse monoclonal anti- 
Fig. 1. Schematic depiction of MMADHC protein and its targeting by premature termination codons (PTC) in cblD disorder. The N-terminal disordered region 
(residues 1–108) and the C-terminal Nitro Reductase-like (NTR) domain (residues 109–296) are indicated. MLS, potential mitochondrial leader sequence, (residues 
1–12). Amino acid numbering is according to accession NP_056517. The exons encoding the different MMADHC regions are shown at the top. The regions targeted by 
PTC from patients with MMA or MMA/HC phenotypes are shown at the bottom. 
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GAPDH (6C5, Santa Cruz Biotechnology). Secondary antibodies conju-
gated with fluorochrome were anti-rabbit or anti-mouse IgG-IRDyeR 
800CW (or IgG-Alexa FluoR 680) (LI-COR Bioscience). 
3. Results 
3.1. MMADHC N-terminal truncated proteoforms 
Alternative usage of initiation Met codons during MMADHC protein 
translation has been found in cells from cblD patients carrying specific 
PTC mutations at MMADHC gene [18]. To understand how genetic 
variability could affect MMADHC protein translation and stability, we 
performed ectopic expression experiments using COS-7 cells transfected 
with recombinant human MMADHC forms bearing epitope tags at its N- 
or C-terminus. First, the expression of a wild type MMADHC form fused 
C-terminally to green fluorescent protein (MMADHC-GFP) was moni-
tored by immunoblot using anti-GFP antibody, in comparison with 
MMADHC-GFP mutated versions in which each MMADHC Met (M1, 
M62, M116, M174, M186, and M290; Fig. 2A) was substituted indi-
vidually by Ala (M1A, M62A, M116A, M174A, M186A, and M290A 
mutations) to abrogate potential translation initiation sites. As shown, 
upon mutation of the Met1 (M1A mutation), two MMADHC-GFP pro-
teoforms were detected corresponding to the usage of Met62 and 
Met116 as translation initiation Met codons, as demonstrated using the 
double mutations M1A/M62A and M1A/M116A. We have named this N- 
terminal truncated proteoforms with a prefix indicating the initiation 
Met (M62-MMADHC, and M116-MMADHC) (Fig. 2B). 
3.2. Protein stability of PTC C-terminal truncated MMADHC variants 
Next, we asked whether PTC described in cblD patients could give 
rise to specific truncated MMADHC variants. Five different MMADHC 
gene codons targeted by nonsense mutations creating PTC (R54X [TGA], 
R158X [TGA], Q180X [TAA], S228X [TGA], and R250X [TGA] muta-
tions) have been described in the literature in cblD patients [7,27–29]. 
In addition, four other MMADHC PTC mutations have been reported in 
databases (Q90X [TAG], R145X [TGA], R216X [TGA], and S228X [TAA] 
mutations) (Table 1; ref. [30–32]). The disease-associated PTC 
MMADHC mutations are mainly found at the MMADHC C-terminal 
domain, with two PTC mutations (R54X and Q90X) found at the disor-
dered MMADHC N-terminal region (Fig. 3A). To analyze the expression 
of PTC MMADHC proteoforms, PTC mutations were generated in a 
MMADHC protein background containing N-terminal hemagglutinin 
(HA) or C-terminal GFP tags (Fig. 3A), and immunoblot analysis was 
performed using anti-GFP (Fig. 3B) or anti-HA (Fig. 3C) antibodies. 
R54X mutation resulted in the translation of two major N-terminal 
truncated MMADHC-GFP proteoforms, whereas Q90X mutation 
rendered one N-terminal truncated MMADHC-GFP proteoform. Further 
mutational analysis using the double mutations R54X/M62A, R54X/ 
M116A, and Q90X/M116A, demonstrated that Met62 and Met116 are 
the initiation Met codons of these proteoforms. No proteoforms starting 
at the other MMADHC Met were consistently detected (Fig. 3B). This 
demonstrates that reinitiation of translation takes place in MMADHC at 
Met62 and Met116 upon termination of translation by a PTC at Arg54, 
and at Met116 upon termination of translation by a PTC at Gln90. These 
results also show that the Met located in the MMADHC amino acid 
sequence after Met116 are not productive to generate MMADHC trun-
cated proteoforms, even in the presence of upstream PTC at the 
MMADHC sequence. 
Next, we analyzed the expression of the N-terminal portion of the 
MMADHC PTC variants using an anti-HA antibody, which recognizes the 
MMADHC N-terminal tag. As shown, MMADHC C-terminal truncations 
of proportionally increased size could be detected starting at R145X up 
to the R250X PTC MMADHC variants (Fig. 3C). 
In summary, our experiments indicate that MMADHC Met62 and 
Met116 are used to reinitiate protein translation upon R54X and Q90X 
PTC mutations, generating two distinct N-terminal MMADHC truncated 
proteins (M62-MMADHC and M116-MMADHC). In addition, we detec-
ted the expression of MMADHC C-terminal truncations caused by PTC 
located at the MMADHC NTR domain. 
Fig. 2. Usage of initiation Met codons in MMADHC protein translation. A. Schematic depiction of the location of the different Met from MMADHC amino acid 
sequence. B. COS-7 cells were transfected with plasmids encoding MMADHC-GFP wild type (wt) or Met to Ala mutations, as indicated, and cell lysates were resolved 
in 10% SDS-PAGE gel and analyzed by immunoblot with anti-GFP antibody. Ø, empty vector. The migrations of MMADHC-GFP, M62-MMADHC-GFP, and M116- 
MMADHC-GFP are indicated, and correspond to the expected molecular weights. 
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3.3. Induction of translational PTC readthrough on MMADHC PTC 
variants 
PTC recognition during protein translation can be interfered using 
specific PTC readthrough-inducing compounds, which permits the syn-
thesis of a full-length protein. We tested the efficiency of PTC read-
through inducers to reconstitute the expression of full-length PTC 
MMADHC-GFP mutations ectopically expressed in COS-7 cells. Fig. 4A 
shows representative experiments of PTC readthrough of the different 
MMADHC PTC variants (Table 1), using as PTC readthrough inducer the 
aminoglycoside G418 (geneticin). Fig. 4B shows the semi-quantification 
of the readthrough efficiency for each PTC variant. As shown, MMADHC 
full-length expression was achieved from MMADHC PTC variants upon 
readthrough induction in a PTC-dependent manner, ranging from 0 to 
20% expression with respect to MMADHC wild type. TGA PTC codons 
responded more efficiently than TAG or TAA, in agreement with pre-
vious PTC readthrough studies [33], with R54X and R250X displaying 
the higher PTC readthrough responses (16% and 8% expression, 
respectively). In the case of R54X, the amount of M62-MMADHC and 
M116-MMADHC N-terminal truncation proteoforms generated upon 
PTC readthrough induction were decreased concomitantly to the gen-
eration of full-length MMADHC. Dose-response of G418 PTC read-
through of MMADHC R250X variant is shown in Fig. 4C, and the PTC 
readthrough response of MMADHC R250X to other aminoglycosides, 
including gentamicin and amikacin [34], is illustrated in Fig. 4D. As 
shown, G418 and gentamicin reconstituted full-length MMADHC R250X 
expression at variable extent (11.5% and 3.5% expression, respectively, 
with respect to MMADHC wild type), whereas amikacin did not induce 
detectable PTC readthrough. In conclusion, PTC-readthrough is suc-
cessfully achieved in specific PTC MMADHC mutations, resulting in the 
reconstitution at a variable extent of the expression of full-length 
MMADHC proteins. 
We further studied by fluorescence microscopy the expression and 
subcellular localization of the R54X and R250X MMADHC mutations 
under control conditions and upon PTC readthrough induction, using 
MMADHC-GFP ectopically expressed in COS-7 cells. In these experi-
ments, a MMADHC variant lacking the N-terminal MLS (MMADHC Δ2- 
12) was also used. Wild-type MMADHC protein showed a punctate 
nucleo-cytosolic localization, whereas MMADHC Δ2-12 displayed a 
more diffuse distribution and lacked the punctate staining (Fig. 5). 
MMADHC R54X displayed a predominant non-punctate distribution 
both under control and readthrough induction conditions, reflecting the 
abundant expression of M62-MMADHC and M116-MMADHC, which 
lack the MLS. MMADHC R250X expression was not detected under 
control conditions, but noticeably staining was observed upon G418 
incubation, displaying a punctate staining pattern in many of the 
transfected cells (Fig. 5). This indicates readthrough -induced reconsti-
tution of expression and subcellular localization of full-length 
MMADHC-GFP. Together, these findings illustrate the differential sub-
cellular localization of wild type MMADHC and MMADHC protein var-
iants lacking the N-terminal region, and confirm the reconstitution by 
induced PTC readthrough of full-length expression of MMADHC PTC 
variants in intact cells. 
4. Discussion 
Mutations generating PTC in disease-associated genes represent the 
single-nucleotide substitutions with a higher pathogenic potential, since 
they produce, in most of the cases, unstable and/or unfunctional trun-
cated proteins. The metabolic cblD-type disorder is a very rare disease in 
which the MMADHC gene is targeted by PTC mutations with relative 
high frequency. Here, we have characterized the MMADHC proteoforms 
generated by disease-associated MMADHC PTC, and disclosed the po-
tential of translational PTC readthrough strategies to reconstitute full- 
length MMADHC protein expression from these PTC-targeted gene 
variants. It should be noted that recombinant tagged forms of MMADHC 
protein have been used in our experiments to facilitate MMADHC 
detection. 
Our MMADHC biochemical expression analysis confirms the alter-
native initiation of protein translation during biosynthesis of MMADHC 
harboring N-terminal PTC mutations [18], and unequivocally identifies 
Met62 and Met116 as the alternatively used initiation Met codons 
during translation of MMADHC R54X and Q90X PTC mutations, 
rendering the proteoforms M62-MMADHC and M116-MMADHC. 
Furthermore, our analysis shows that mutation of Met1 (M1A muta-
tion) also results in the synthesis of M62-MMADHC and Met116- 
MMADHC. This is relevant since a MMADHC M1R homozygous muta-
tion (c.2 T > G) has been found in cblD patients with MMA isolated 
phenotype [35]. Additional MMADHC frameshift mutations have been 
reported generating PTC at the N-terminal MMADHC region [7,18,36], 
which will also likely use alternative initiation of translation at Met62 
and/or Met116. It can be hypothesized that patients harboring these N- 
terminal MMADHC mutations express M62-MMADHC and M116- 
MMADHC. Nonsense-mediated alternative translation initiation has 
Table 1 
Germline MMADHC PTC mutations1.  
Mutation2 Amino acid substitution2 Codon3 Exon Patient phenotype4 Reported in databases5 Ref.6 
HGMD ClinVar ExAC/gnomAD Exome Variant 
c.160C > T p.(Arg54Term)7 / R54X TCT TGA ACA 4 cblD MMA + + [7] 
c.268C > T p.(Gln90Term) / Q90X TCA TAG AAG 4    +
c.433A > T p.(Arg145Term) / R145X GCC TGA GTA 5    +
c.472C > T p.(Arg158Term) / R158X CTG TGA AAA 5 cblD MMA/HC + + + [27] 
c.538C > T p.(Gln180Term) / Q180X ACA TAA AAA 6 cblD MMA/HC + + [29] 
c.646C > T p.(Arg216Term) / R216X CTT TGA GCT 7    +
c.683C > A 
c.683C > G 
p.(Ser228Term) / S228X CCA TAA TCT 
CCA TGA TCT 
7  
cblD MMA/HC  +
+
+ [28] 
c.748C > T p.(Arg250Ter)8 / R250X TAC TGA CAT 8 cblD MMA/HC + + + [7,23]  
1 Nonsense mutations generating premature termination codons (PTC) at MMADHC gene and reported in the literature or in databases are indicated. Frameshift 
mutations that create downstream PTC are not included. 
2 Nucleotide and amino acid substitutions are indicated following HGVS recommended nomenclature, as well as with single-letter code amino acid nomenclature. 
Nucleotide and amino acid numbering corresponds to accessions NM_015702.3 and NP_056517.1, respectively. 
3 The PTC is underlined and flanked by the adjacent codons. 
4 MMA, Methylmalonic aciduria; HC, Homocystinuria. Note that in some cases the patient phenotype is not available 
5 HGMD, Human Gene Mutation Database [32]; ClinVar (NCBI) [30]; Exome Aggregation Consortium (ExAC), Genome Aggregation Database (gnomAD) (Broad 
Institute) [31]; Exome Variant Server (NHLBI Exome Sequencing Project). 
6 Original references (to the best of our knowledge) for mutation-encoding variants from patients are provided. 
7 Heterozygous carrier: c.160C>T / c.307_324dup. 
8 Heterozygous carrier in ref [23]: c.748C>T / c.438_442del 
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been described before, in some cases in association with disease- 
associated mutations that create a PTC, suggesting that reinitiation of 
translation after a PTC is a general mechanism [37–39]. It has been 
proposed that the PTC must be relatively close to both the canonical 
upstream initiation site and to the downstream reinitiation site, 
although there are variations in the reported minimal distances between 
these elements [38,40,41]. In our analysis, reinitiation at MMADHC 
Met174 (or the rest of downstream Met) from MMADHC R54X or Q90X 
was not detected. In addition, no reinitiation was detected at Met174 (or 
the rest of downstream Met) from PTC located immediately upstream, 
including those at positions Arg145 (R145X mutation) and Arg158 
(R158X mutation). It is conceivable that M62-MMADHC and M116- 
MMADHC, which possess a complete NTR domain, are stable proteins 
with potential functionality [15]. On the other hand, initiation at Met 
downstream Met116 would generate N-terminal truncated NTR do-
mains, which are likely to lack function. This is in agreement with the 
phenotypes shown by patients harboring MMADHC N-terminal trun-
cated mutations [7,17,18]. In addition, we have found variable 
expression of MMADHC C-terminal truncated forms in the variants 
targeted by PTC downstream of Gln90, suggesting the existence of 
MMADHC proteoforms with NTR C-terminal truncated domains. Since 
most of these MMADHC C-terminal truncated forms lack a large portion 
of the NTR domain, they are likely to have impaired binding to 
MMACHC and function. Interestingly, the MMADHC R250X mutation, a 
prevalent PTC mutation associated to late-onset cblD MMA/HC disorder 
[23], generates an almost complete NTR domain, but it lacks the Cys261 
which acts as the sulfur ligand to cbl bound to MMACHC [16]. This may 
help to understand the specific late-onset phenotype associated to the 
R250X mutation, and opens the possibility that this mutation is not 
completely deleterious for all MMADHC functions during early devel-
opment. Further work is required to ascertain the molecular mecha-
nisms that drive MMADHC protein variants stability and function in 
cells. 
Our PTC readthrough analysis on the collection of MMADHC PTC 
mutations associated to cblD disorder has unveiled the potential to 
restore expression and subcellular localization of full-length MMADHC 
in specific groups of patients. Experiments in a genuine genomic back-
ground are required to reinforce these findings in a more physiological 
context. Several MMADHC PTC mutations, including R54X, R158X, 
R216X, and R250X TGA mutations, displayed a detectable PTC read-
through response to the aminoglycoside G418. On the other hand, the 
MMADHC PTC TAA mutations, including Q180X and S228X, did not 
respond to G418 PTC readthrough induction. This is in agreement with 
the reported differential PTC readthrough efficiency depending of the 
PTC type (TGA > TAG>TAA), which is also affected by the local 
nucleotide sequences close to the PTC [33,42,43]. Importantly, in the 
Fig. 3. Protein translation of MMADHC PTC mutations associated to cblD disorder. A. Schematic depiction of the location of the different cblD-associated MMADHC 
mutations causing PTC. B. COS-7 cells were transfected with plasmids encoding MMADHC-GFP wild type (wt) or PTC mutations, as indicated, and cell lysates were 
resolved in 10% SDS-PAGE gel and analyzed by immunoblot with anti-GFP antibody. C. COS-7 cells were transfected with plasmids encoding HA-MMADHC wild type 
(wt) or PTC mutations, as indicated, and cell lysates were resolved in 12% SDS-PAGE gel and analyzed by immunoblot with anti-HA antibody. Ø, empty vector. In B, 
the migrations of MMADHC-GFP, M62-MMADHC-GFP, and M116-MMADHC-GFP are indicated, and correspond to the expected molecular weights. 
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case of MMADHC R54X, the PTC readthrough-induced expression of 
full-length MMADHC was accompanied by a decrease in the synthesis of 
the pathogenic M62-MMADHC and M116-MMADHC proteoforms. In the 
case of MMADHC R250X, the MMADHC PTC variant more frequently 
found in patients [23], partial restoration of expression and subcellular 
location was achieved upon readthrough induction. 
Although newborn screening, where available, is helping in the early 
diagnosis of cbl-related disorders and its appropriate pharmacological 
therapeutic treatment, the clinical benefits of early treatment in cblD 
defect remain uncertain [44,45]. There is limited experience with OH- 
Cbl treatment in cblD-MMA/HC disease, but there seems to be a 
response to treatment in some patients [44-46], and complementary 
treatments could help to improve patient welfare. PTC readthrough 
reconstitution has been explored for stop codon-mutated MMUT 
[47,48], and the non-aminoglycoside PTC readthrough inducer Ataluren 
(PTC124) has been tested in a clinical trial (NCT01141075) on MMA 
patients with PTC mutations in the MMUT gene or in the genes MMAA or 
MMAB, involved in conversion of cbl to AdoCbl. Our study addresses the 
potential of readthrough to counterbalance MMADHC deficiency in cblD 
patients, and emphasizes the importance of individual genetic and 
biochemical analysis of MMADHC from each patient, not only to obtain 
an accurate genetic diagnosis that guide standard interventions, but also 
Fig. 4. Readthrough response of MMADHC PTC mutations associated to cblD disorder. COS-7 cells were transfected and analyzed as in Fig. 3. A. Cells expressing 
MMADHC-GFP wild type (wt) or the different cblD-associated PTC mutations were kept untreated or were treated for 24 h with G418 (200 μg/ml), and cell lysates 
were analyzed by immunoblot with anti-GFP antibody. Arrows indicate the migration of the full-length MMADHC-GFP proteins. Anti-GAPDH is shown as a loading 
control. B. Semi-quantification of PTC readthrough efficiency of MMADHC-GFP PTC variants upon G418 treatment, from cells treated as in A. C. Cells expressing 
MMADHC-GFP R250X were treated for 24 h with the indicated concentrations of G418, and cell lysates were analyzed by immunoblot with anti-GFP antibody. A 
representative experiment is shown at the top, and semi-quantification is shown at the bottom. D. Cells expressing MMADHC-GFP R250X were treated for 24 h with 
different PTC readthrough inducers (G418, 200 μg/ml; Gentamicin, 800 μg/ml; Amikacin, 2 mg/ml), and cell lysates were analyzed by immunoblot with anti-GFP 
antibody. A representative experiment is shown at the top, and semi-quantification is shown at the bottom. In B, C, and D, data are shown as the mean ± s.d. of PTC 
readthrough efficiency from at least two independent experiments, calculated as described under Materials and Methods. 
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to provide information on the actionability by alternative precision 
therapies. This is well illustrated by our findings on the PTC-specific 
response to MMADHC expression restoration achieved upon PTC read-
through induction by the aminoglycoside G418. Since many PTC read-
through inducers experimentally used (including G418) display 
undesired toxicity, searching for highly effective and non-toxic PTC- 
readthrough-inducing compounds is currently under intense scrutiny in 
a variety of human diseases, including inborn metabolic diseases 
[49,50]. In addition, the identity of the amino acid incorporated at the 
PTC position during readthrough is variable [51], requiring the analysis 
of protein stability and function of MMADHC restored upon PTC 
readthrough to further inform on the potential therapeutic efficacy of 
this approach for cblD disorder. 
The degradation of mRNAs harboring PTC is triggered by nonsense- 
mediated mRNA decay (NMD) mechanisms [52,53]. Importantly, PTC 
readthrough not only reconstitutes the expression of full-length proteins 
whose encoding genes are targeted by PTC, but also inhibits NMD of 
their transcripts [54]. In the case of specific MMADHC PTC mutations, 
NMD has been shown to be partially reverted by the NMD inhibitor 
emetine [18]. We hypothesize that low toxicity PTC readthrough 
inducing agents, alone or in combination with NMD inhibitors, could be 
beneficial for a group of cblD patients harboring specific PTC mutations. 
Fig. 5. Subcellular localization of MMADHC variants upon PTC-readthrough induction. A. Schematic depiction of the different MMADHC-GFP proteins analyzed by 
immunofluorescence. B. COS-7 cells were transfected with plasmids encoding MMADHC-GFP wild type (wt) or PTC mutations (R54X, R250X), in the presence or in 
the absence of G418, as indicated. A MLS-deleted variant (Δ2-12) was also included. Nuclei were stained with Hoechst (blue), and cells were directly visualized by 
standard fluorescence microscopy. MMADHC-GFP (green), but not MMADHC-GFP Δ2-12 or MMADHC-GFP R54X, displayed a punctate staining. Note in the left 
panel the punctate expression pattern in MMADHC-GFP R250X upon G418 PTC-readthrough induction. 
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